Does The Early Development Of Metastases Carry The Same Significance As Metastases At Diagnosis?

Robert Grimer, Michael Parry, Lee Jeys

The Birmingham Orthopaedic Oncology Service, Royal Orthopaedic Hospital, Bristol

Road South, Birmingham, B31 2AP
Abstract

Background: It is common practice in cancer registries, to consider patients who develop metastases within four months of diagnosis with those who have present with metastases.

Purpose: To establish whether survivorship is affected by early metastases for patients presenting with a sarcoma.

Methods: Retrospective analysis of a prospectively compiled database identifying 6330 patients with a newly diagnosed osseous (3318) or soft tissue sarcoma (3012) including information on prognostic demographic and tumour related factors.

Results: 867 patients presented with metastases (13.7%), 134 developed metastases within 4 months of diagnosis (2.1%) and 11 developed metastases within 6 months (1.7%). Early metastases were associated with high tumour grade and large size and occurred as frequently in bone and soft tissue sarcoma. A strong for early metastases was secondary sarcoma, radiation induced sarcoma and dedifferentiated chondrosarcoma. 5-year survival was 13% with metastases at diagnosis and 5% for early metastases (p<0.001). Relapse at 6 and 12 months was associated with a poor prognosis regardless of tumour type, when compared to those with metastases at diagnosis. Relapse was an independent risk factor for prognosis at 4-months (HR 8.9) which compared to a HR of 5.3 for those with metastases at diagnosis. A common risk for relapse was a poor response to chemotherapy whilst those surviving beyond 5-years had metastases that could be surgically removed.
Conclusion: The development of metastases within 4-months of diagnosis is a poor prognostic indicator when compared to patients presenting with metastases. This may represent a failure to respond to first line therapy.